| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7138390 | INTERCEPT PHARMS INC | Steroids as agonists for FXR |
Nov, 2022
(1 year, 5 months ago) | |
| USRE48286 | INTERCEPT PHARMS INC | Steroids as agonists for FXR |
Feb, 2027
(2 years from now) | |
| US10174073 | INTERCEPT PHARMS INC | Preparation and uses of obeticholic acid |
Jun, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8377916 | INTERCEPT PHARMS INC | Steroids as agonists for FXR |
Feb, 2022
(2 years ago) | |
| US8058267 | INTERCEPT PHARMS INC | Steroids as agonists for FXR |
Feb, 2022
(2 years ago) | |
| US9238673 | INTERCEPT PHARMS INC | Preparation and uses of obeticholic acid |
Jun, 2033
(9 years from now) | |
| US10047117 | INTERCEPT PHARMS INC | Preparation and uses of obeticholic acid |
Sep, 2033
(9 years from now) | |
| US10052337 | INTERCEPT PHARMS INC | Compositions of obeticholic acid and methods of use |
Apr, 2036
(12 years from now) | |
| US10758549 | INTERCEPT PHARMS INC | Compositions of obeticholic acid and methods of use |
Apr, 2036
(12 years from now) | |
| US10751349 | INTERCEPT PHARMS INC | Compositions of obeticholic acid and methods of use |
Apr, 2036
(12 years from now) | |
Ocaliva is owned by Intercept Pharms Inc.
Ocaliva contains Obeticholic Acid.
Ocaliva has a total of 10 drug patents out of which 3 drug patents have expired.
Expired drug patents of Ocaliva are:
- US8377916
- US8058267
- US7138390
Ocaliva was authorised for market use on 27 May, 2016.
Ocaliva is available in tablet;oral dosage forms.
Ocaliva can be used as treatment of primary biliary cholangitis (pbc), treatment of primary biliary cholangitis (pbc) in combination with ursodeoxycholic acid (udca) in adults with an inadequate response to udca, or as monotherapy in adults unable to tolerate udca.
Drug patent challenges can be filed against Ocaliva from 27 May, 2020.
The generics of Ocaliva are possible to be released after 26 April, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | May 27, 2023 |
| Orphan Drug Exclusivity(ODE-119) | May 27, 2023 |
| New Chemical Entity Exclusivity(NCE) | May 27, 2021 |
Drugs and Companies using OBETICHOLIC ACID ingredient
NCE-1 date: 27 May, 2020
Market Authorisation Date: 27 May, 2016
Treatment: Treatment of primary biliary cholangitis (pbc); Treatment of primary biliary cholangitis (pbc) in combination with ursodeoxycholic acid (udca) in adults with an inadequate response to udca, or as mono...
Dosage: TABLET;ORAL
OCALIVA family patents
